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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is
rimegepant an effective treatment for acute migraine pain in adults?”
STUDY DESIGN: A systematic review of three, peer-reviewed randomized placebo-controlled
trials (RCT’s).
DATA SOURCES: All studies were obtained from PubMed and were published in English in
peer-reviewed journals between 2014-2019. The articles were selected based on their relevance
to the clinical question posed in the objective and their inclusion of patient oriented outcomes.
OUTCOMES MEASURED: The main outcome being assessed in all articles was freedom from
pain. The absence/presence of pain was self-reported by patients two hours post
rimegepant/placebo dose in all trials.
RESULTS: All RCT’s found rimegepant to be superior in eliminating migraine pain compared
to the placebo group. Croop et al. (2019) found that 21.2% of patients treated with rimegepant
had freedom from pain 2 hours postdose while only 10.9% of patients treated with the placebo
achieved freedom of pain 2 hours postdose. The study was statistically significant (p-value <
0.0001) and had a large treatment effect based on a calculated NNT of 10. Lipton et al. (2019)
found that 19.6% of patients treated with rimegepant had freedom from pain 2 hours postdose
while only 12.0% of patients treated with the placebo achieved freedom from pain 2 hours
postdose. The study was statistically significant (p-value < 0.001) and had a large treatment
effect based on a calculated NNT of 13. Marcus et al. (2014) found that 31.4% of patients
treated with rimegepant had freedom from pain 2 hours postdose while only 15.3% of patients
treated with the placebo achieved freedom from pain 2 hours postdose. The study was
statistically significant (p-value ≤ 0.002) and had a large treatment effect based on a calculated
NNT of 7.
CONCLUSIONS: All three studies found rimegepant to be more effective at eliminating acute
migraine pain of moderate to severe intensity compared to the placebo. Statistically significant pvalues as well as large treatment effects were found in each study. Future research should be
conducted looking at safety among individuals with cardiovascular disease.
KEYWORDS: rimegepant, migraine treatment
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INTRODUCTION
Migraine headaches are a chronic neurologic disorder characterized by recurrent
moderate to severe unilateral throbbing pain, often associated with nausea, vomiting,
photophobia, and phonophobia. They can be distinguished from other types of headaches based
on their severity, laterality, and associated symptoms (nausea, vomiting, photophobia,
phonophobia). Migraine headaches are often separated into two categories, with an aura or
without an aura. An aura is sensory anomaly that precedes a migraine headache and can include
but is not limited to visual, auditory, sensory, speech, and/or motor disturbances.
Migraine headaches are commonly seen throughout the world, often presenting in many
different clinical settings. An estimated 1.04 billion individuals worldwide experienced a
migraine headache in 2016.1 In the US alone, 39 million individuals are affected by migraine
headaches, with 28 million being female.2 With migraines being among the most common
neurologic disorders affecting the US population, the financial burden can be substantial. In the
United States, the economic burden of migraine headaches is approximately $78 billion
annually.2 With migraine headaches accounting for 800,000 emergency department visits
annually,3 substantial amounts of medical resources are being allocated to the treatment of
migraines. Finding an effective treatment for migraine headaches can not only decrease the
economic burden of migraine management, but also allow allocation of medical resources to
other areas of need.
The pathophysiology of migraine headaches isn’t fully understood, but it is believed to be
the result of neuronal dysfunction related to the trigeminal nerve.4 Dysfunction in the trigeminal
nerve results in the release of vasoactive neuropeptides which leads to sensitization and
neurogenic inflammation resulting in a migraine.4 One of the major vasoactive neuropeptides
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believed to contribute to the development of a migraine headache is calcitonin gene-related
peptide (CGRP).
Traditionally, therapy for migraine headaches has involved rest, IV fluids, antiemetics,
simple analgesics (NSAIDS, aspirin, acetaminophen), ergotamines, and triptans, which are 5HT1b/1d receptor agonists. These established methods of acute migraine treatment mentioned
have been proven to have some success in the treatment of acute migraines. However, triptans
and ergotamines are both contraindicated in patients with cardiovascular disease. Also, current
therapies may not be effective or tolerable for all patients. Since rimegepant is a CGRP
antagonist, it has a different mechanism of action compared to any current therapies for acute
migraine attacks, including triptans and ergotamines. Therefore, rimegepant could be an effective
treatment option for acute migraine pain, especially in individuals where current therapies have
proven to be ineffective, poorly tolerated, or contraindicated.
OBJECTIVE
The objective of this systematic review is to determine whether or not “Is rimegepant an
effective treatment for acute migraine pain in adults?”
METHODS
Three randomized placebo-controlled trials comparing rimegepant intervention to a
placebo in the treatment of acute migraine pain of moderate to severe intensity were found using
the key words “migraine treatment” and “rimegepant” via PubMed. Criteria for the articles
included in this systematic review were selected by the author of this paper based on their
relevance to the question, Is rimegepant an effective treatment for acute migraine pain in adults,
as well as their inclusion of patient oriented outcomes (POEMS), specifically freedom from
migraine pain. All three articles selected were published in peer-reviewed journals written in
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English in the years 2014 and 2019. Exclusion criteria included articles published prior to 2011,
non peer-reviewed articles, and articles with secondary study design.
The population criteria used for this review included adults (18 or older) with at least a 1year history of migraines who were randomly assigned to a treatment group receiving either
rimegepant 75 mg or a placebo to treat an acute migraine attack of moderate to severe intensity.
The selected articles compared the intervention rimegepant 75 mg to a control group receiving a
placebo with the measured outcome of freedom from pain 2 hours post dose. Statistic values
reported and used included p-values and NNT. Demographics of each study can be found in
Table 1.
OUTCOMES MEASURED
The primary outcome measured in all three RCTs was freedom from pain 2 hours post
rimegepant/placebo dose following an acute migraine attack of moderate to severe intensity.
Patients were instructed to self-report the absence or presence of pain 2 hours post
rimegepant/placebo dose in an electronic diary.
RESULTS
Croop et al.5 performed a randomized double-blind placebo-controlled trial to determine
the efficacy of rimegepant 75 mg versus placebo in the treatment of acute migraine pain of
moderate to severe intensity in adults. The trial took place across 69 study locations across the
United States between February 27 – August 28, 2018. Participants were required to be 18 years
of age or older and have a 1-year history of migraines with or without an aura per the criteria of
the 3rd Edition of International Classification of Headache Disorders (beta version).5 More
inclusion and exclusion criteria can be found in Table 1.
A 1:1 ratio was used to randomly assign participants via a web system independently
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Table 1. Demographics & Characteristics of Included Studies
Study Type # Pts Age
Inclusion
Exclusion
(yrs)
Criteria
Criteria
Croop5
(2019)

RCT

1375

Adults
>18
years
old

Lipton6
(2019)

RCT

1086

Adults
>18
years
old

Marcus7
(2014)

RCT

320

Adults
18-65
years
old

Patients > 18 y.o. with at least a
one year history of migraine w/
or w/o an aura. Migraine onset
before age 50; Must be able to
distinguish migraine attacks
from tension or cluster headache.
2-8 migraine attacks of
moderate/severe intensity per
month, <15 days per month with
headache within the past 3
months. Stable dose of
preventive migraine medication
at least 3 months before trial
entry
Patients > 18 y.o. with at least a
1 year history of migraine, with
onset before 50 y.o.; headache <
15 days per month during
previous 3 months. 2-8 migraine
attacks
of moderate/severe intensity per
month. Stable dose of preventive
migraine medication at least 3
months before entry to trial

18-65 y.o. w/ > 1 year history of
migraine w/ or w/o an aura.
Migraine onset before 50 y.o,
with migraine duration of 4-72
hours. Headache for < 15 days
per month during previous 3
months. 2-7 migraine attacks of
moderate/severe intensity per
month within 3 months of
screening Must be able to
distinguish migraine attacks
from tension or cluster headache.
Stable dose of preventive
migraine medication at least 3
months before trial entry.

W/
D

Interventions

History of any
clinically significant
medical condition,
including substance
abuse that could
interfere with the
study or put patients
at health risk

24

Rimegepant
VS. Placebo

History of any
clinically significant
medical condition,
including substance
abuse that could
interfere with the
study or put patients
at risk. Received
biologic agents
within 90 days
Received
nonbiologic agents
within 30 days
Patients with history
of basilar or
hemiplegic
migraines; any
patients who didn’t
get relief from
migraines from
triptans. History of
any clinically
significant medical
condition,
including substance
abuse as well as any
medications that
could interfere with
the study or put
patients at health
risk.
Pregnant/breastfeedi
ng women or
women who didn’t
use contraceptives

6

Rimegepant
VS. Placebo

24

Rimegepant
VS. Placebo
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operated by a research organization not involved with any other aspects of the trial to either
rimegepant or placebo. The treatment assignments of rimegepant and placebo were hidden from
all participates, investigators, and study staff. Both rimegepant and placebo were matched in
flavor, appearance, and presentation. Participants were instructed to sublingually administer a
single dose of the study medication assigned to them in the event of a single acute migraine
attack of moderate to severe intensity over the 45 day trial period. Participants were instructed to
document their symptoms and pain at set timepoints over a 48 hour period post study medication
dose in a provided electronic diary. This review specifically focused on the endpoint of freedom
from pain at the 2 hours post dose timepoint for each study medication.
Of the 1375 participates randomly assigned to rimegepant or placebo who experienced a
qualifying migraine, 21.2% of participants that received rimegepant reported freedom from pain
at 2 hours post dose (Table 2).5 Only 10.9% of participants that received placebo reported
freedom from pain at 2 hours post dose (Table 2).5 The study was statistically significant with a
p-value of p<0.0001 and had a large treatment effect based on a calculated NNT of 10. Results of
this study indicate rimegepant was more effective than placebo at achieving freedom from pain.5
Table 2. Comparison of Freedom from Pain of the Study Groups in Croop et al.5
Rimegepant 75 mg
Placebo

Freedom from Pain
at 2 Hours Post
Dose

Events/patients

Events/patients

142/669 (21.2%)

74/682 (10.9%)

p-value < 0.0001

Lipton et al.6 performed a similar randomized double-blind placebo-controlled trial to
determine the efficacy of rimegepant 75 mg versus placebo in the treatment of acute migraine
pain of moderate to severe intensity in adults. The trial took place across 49 study locations
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across the United States between July 2017 - January 2018. Participants were required to be 18
years of age or older and have a 1-year history of migraines with or without an aura per the
criteria of the 3rd International Classification of Headache Disorders (beta version).5 More
inclusion and exclusion criteria can be found in Table 1.
Similar to Croop et al,5 a 1:1 ratio was used to randomly assign participants via a web
system to the rimegepant treatment group or placebo treatment group. Both rimegepant and
placebo were matched in flavor, appearance, and presentation. Participants were instructed to
administer a single dose of the study medication assigned to them at the occurrence of a single
acute migraine attack of moderate to severe intensity over the 45 day trial period. Participants
were instructed to document their symptoms and pain at set timepoints over a 48 hour period
post study medication dose in a provided electronic diary. This review specifically focused on
the endpoint of freedom from pain at the 2 hours post dose timepoint for each study medication.
Of the 1086 participates randomly assigned to rimegepant or placebo who received the
study medication dose, 19.6% of participants that received rimegepant reported freedom from
pain at 2 hours post dose (Table 3).6 Only 12.0% of participants that received placebo reported
freedom from pain at 2 hours post dose (Table 3).6 The study was statistically significant with a
p-value < 0.001 and had a large treatment effect based on a calculated NNT of 13. Results of this
study indicated rimegepant was more effective than placebo at achieving freedom from pain.6
Table 3. Comparison of Freedom from Pain of the Study Groups in Lipton et al.6
Rimegepant 75 mg
Placebo

Freedom from Pain
at 2 Hours Post
Dose

Events/patients

Events/patients

105/537 (19.6%)

64/535 (12.0%)

p-value < 0.001
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Marcus et al.7 performed a randomized double-blind placebo-controlled trial similar to
the two studies mentioned above. However, the Marcus et al.7 trial differed in that it investigated
the efficacy of rimegepant at six different doses (10mg, 25mg, 75mg, 150mg, 300mg, and
600mg) versus placebo versus oral sumatriptan 100 mg in the treatment of acute migraine pain of
moderate to severe intensity in adults. The trial took place in the United States between October
2011 – May 2012. Participants were required to be 18-65 years of age and have a 1-year history
of migraines with or without an aura. More inclusion and exclusion criteria can be found in
Table 1.
A fixed ratio was used to randomly assign participants to the treatment group or placebo
group. The treatment group was then further allocated randomly into groups receiving varying
doses of rimegepant and sumatriptan 100 mg. Participants were instructed to administer the study
medication assigned to them at the occurrence of a single acute migraine attack of moderate to
severe intensity over the 45 day trial period. Participants were then instructed to document their
symptoms and pain at set timepoints over a 48 hour period post study medication dose in a
provided electronic diary. This review specifically focused on the endpoint of freedom from pain
at the 2 hours post dose timepoint for rimegepant 75 mg and placebo.
Of the 320 participates randomly assigned to rimegepant 75 mg or placebo who
experienced a qualifying migraine, 31.4% of participants that received rimegepant reported
freedom from pain at 2 hours post dose (Table 4).7 Only 15.3% of participants that received the
placebo reported freedom from pain at 2 hours post dose (Table 4).7 The study was statistically
significant with a p-value of p ≤ 0.002 and had a large treatment effect based on a calculated
NNT of 7. Results of this study indicate rimegepant 75 mg was more effective than placebo at
achieving freedom from pain.7
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Table 4. Comparison of Freedom from Pain of the Study Groups in Marcus et al.7
Rimegepant 75 mg
Placebo

Freedom from Pain
at 2 Hours Post
Dose

Events/patients

Events/patients

27/86 (31.4%)

31/203 (15.3%)

p-value ≤ 0.002

DISCUSSION
This systematic review assessed the efficacy of rimegepant as a treatment for acute
migraine pain of moderate to severe intensity in adults. All three trials evaluated showed a
statistically significant difference between rimegepant and placebo in achieving freedom from
pain.5-7 In each study, rimegepant was significantly better at eliminating migraine pain compared
to a placebo.5-7
All three studies evaluated in this review randomly assigned patients to treatment groups,
concealing participants from assignments while blinding participants, clinicians, and study
workers.5-7 In addition, both treatment groups (rimegepant and placebo) exhibited similar
demographics and baseline characteristics including but not limited to sex, ethnicity, race, and
frequency of migraine attacks across all three studies. Implementation of these measures added
to the validity of each study.
The three studies evaluated were not without limitations. Because each study
implemented a single-attack design, consistency of rimegepant’s efficacy over multiple attacks
couldn’t be established. In addition, “worst case” analysis of participants lost to follow-up was
not performed in any of the studies. Additionally, Marcus et al.7 was limited by its small sample
size compared to the other two studies. A final limitation worth mentioning involved the author’s
method of article selection for this systematic review. Because PubMed was the only database
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utilized for research, other studies that could have better answered the author’s original question
may have been excluded.
Both Croop et al.5 and Lipton et al.6 found safety and tolerability to be similar between
participants treated with rimegepant versus placebo with nausea being the most common adverse
effect noted.5,6 Rimegepant has recently received FDA approval for treating acute migraines as
of February 2020.8 The only known contraindication to rimegepant is hypersensitivity to
rimegepant.9
CONCLUSION
Based on the results of the three randomized placebo-controlled trials evaluated in this
systematic review, rimegepant is an effective treatment for acute migraine pain in adults. All the
studies were statistically significant with large treatment effects.
More recent studies involving rimegepant that were not included in this systematic
review have evaluated the medication’s long-term safety, use as preventive therapy, as well as
the its safety in subgroups of individuals where triptans are poorly tolerated or not effective.10,11
Rimegepant was recently FDA approved for the preventive treatment of migraines in May 2021,
making it FDA approved for both acute therapy and preventative therapy.8 Future research could
be expanded to patient populations that include individuals under the age of 18 as well as
individuals with cardiovascular disease. With the success of CGRP antagonists, future research
could also target other vasoactive neuropeptide pathways as possibilities for new therapies.
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